Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Viskase Holdings Inc's Business Segments
Viskase Holdings Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
4
Largest Segment
Emea Segment
Total Revenue
$ 86
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Emea Segment60%
- North America Segment42.4%
- South America Segment13.2%
- Asia Segment9.2%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Emea Segment | $ 52 | 60% |
| North America Segment | $ 36 | 42.4% |
| South America Segment | $ 11 | 13.2% |
1 more segments available
Sign in to unlock the full Viskase Holdings Inc dataset.
Revenue by Product & Service Category - Q1 FY2026
- Nojax Product Line54.3%
- Fibrous Product Line28.7%
- Plastic Product Line12.5%
- Traded Goods Product Line2.4%
- Large Product Line1.9%
- Other Product Line0.9%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Nojax Product Line | $ 47 | 54.3% |
| Fibrous Product Line | $ 25 | 28.7% |
| Plastic Product Line | $ 11 | 12.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
3 more categories available
Sign in to unlock the full Viskase Holdings Inc dataset.
Description of Viskase Holdings Inc
Enzon Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for the treatment of various diseases. The company was founded in 1981 and is headquartered in Bridgewater, New Jersey, United States.
Enzon Pharmaceuticals has a diverse portfolio of products and technologies, which include antibody drug conjugates, recombinant proteins, and small molecules. The company's products are primarily used in the areas of oncology, autoimmune diseases, and infectious diseases.
One of the key areas of focus for Enzon Pharmaceuticals is the research and development of antibody drug conjugates (ADCs). ADCs are a type of targeted therapy in which a monoclonal antibody is conjugated with a cytotoxic drug. This allows the antibody to specifically target cancer cells, delivering the drug directly to the tumor site while minimizing damage to healthy cells.
Enzon Pharmaceuticals has developed multiple ADC candidates, including PEG-SN38, PEG-L-asparaginase, and PEG-interferon beta-1b. These candidates are currently in various stages of preclinical and clinical development, with the goal of providing more effective and targeted treatment options for cancer patients.
In addition to ADCs, Enzon Pharmaceuticals also has a strong presence in the field of recombinant protein therapy. The company's recombinant protein products include PEG-INTRON A, which is a long-acting form of interferon alpha used to treat hepatitis C and certain types of cancer.
Enzon Pharmaceuticals has a dedicated research and development team that works on discovering and developing new drugs and technologies. The company collaborates with academic institutions, research organizations, and other biopharmaceutical companies to further its research and bring new products to market.
Enzon Pharmaceuticals also has a strong commitment to commercializing its products globally. The company has established strategic partnerships and licensing agreements with pharmaceutical companies around the world to distribute and market its products.
Overall, Enzon Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for the treatment of various diseases. The company's diverse portfolio of products, including antibody drug conjugates and recombinant proteins, demonstrates its dedication to bringing effective and targeted treatment options to patients worldwide.
Enzon Pharmaceuticals has a diverse portfolio of products and technologies, which include antibody drug conjugates, recombinant proteins, and small molecules. The company's products are primarily used in the areas of oncology, autoimmune diseases, and infectious diseases.
One of the key areas of focus for Enzon Pharmaceuticals is the research and development of antibody drug conjugates (ADCs). ADCs are a type of targeted therapy in which a monoclonal antibody is conjugated with a cytotoxic drug. This allows the antibody to specifically target cancer cells, delivering the drug directly to the tumor site while minimizing damage to healthy cells.
Enzon Pharmaceuticals has developed multiple ADC candidates, including PEG-SN38, PEG-L-asparaginase, and PEG-interferon beta-1b. These candidates are currently in various stages of preclinical and clinical development, with the goal of providing more effective and targeted treatment options for cancer patients.
In addition to ADCs, Enzon Pharmaceuticals also has a strong presence in the field of recombinant protein therapy. The company's recombinant protein products include PEG-INTRON A, which is a long-acting form of interferon alpha used to treat hepatitis C and certain types of cancer.
Enzon Pharmaceuticals has a dedicated research and development team that works on discovering and developing new drugs and technologies. The company collaborates with academic institutions, research organizations, and other biopharmaceutical companies to further its research and bring new products to market.
Enzon Pharmaceuticals also has a strong commitment to commercializing its products globally. The company has established strategic partnerships and licensing agreements with pharmaceutical companies around the world to distribute and market its products.
Overall, Enzon Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for the treatment of various diseases. The company's diverse portfolio of products, including antibody drug conjugates and recombinant proteins, demonstrates its dedication to bringing effective and targeted treatment options to patients worldwide.
Enzon Pharmaceuticals Inc. is a biopharmaceutical company that is deeply involved in the development and commercialization of innovative therapeutics aimed primarily at treating cancer and other debilitating conditions. The company operates through several distinct segments that each leverage their specialized capabilities and expertise, offering a comprehensive suite of products and services. Below is an extensive description of these segments:
1. Contract Manufacturing and Services
Enzon Pharmaceuticals provides robust contract manufacturing and services tailored to the needs of pharmaceutical and biotechnology companies. This segment encompasses a wide array of offerings:
- Process Development: Enzon’s team assists clients in optimizing manufacturing processes for drug candidates, ensuring they are cost-effective and scalable for production.
- Formulation Development: They provide expertise in developing drug formulations that enhance the delivery and effectiveness of active pharmaceutical ingredients (APIs).
- Clinical Manufacturing: The company manages the production scale necessary for clinical trials, adhering to stringent regulatory standards to ensure safety and efficacy in studies.
- Commercial Manufacturing: Enzon’s facilities are equipped to handle large-scale production to meet market demands, ensuring timely delivery of products.
- Analytical Testing: Comprehensive analytical services are offered to confirm the quality, purity, and potency of pharmaceuticals, utilizing advanced testing methodologies to comply with regulatory requirements.
By capitalizing on their state-of-the-art facilities and industry knowledge, Enzon Pharmaceuticals plays a critical role in enabling other companies to successfully bring their therapies to market.
Proprietary Drug Development
Enzon Pharmaceuticals invests significantly in proprietary drug development, focusing on innovative therapeutic candidates that target unmet medical needs. Key aspects include:
- Drug Discovery: Utilizing advanced drug design and screening technologies, Enzon seeks to identify novel compounds that have therapeutic potential.
- Clinical Development: The company manages the progression of drug candidates through various phases of clinical trials, rigorously assessing safety and efficacy for regulatory submissions.
- Therapeutic Areas: Enzons drug development efforts target a variety of diseases, with a primary focus on cancer and autoimmune disorders, striving to improve treatment outcomes for patients.
PEGylation Platform
The PEGylation platform developed by Enzon Pharmaceuticals is a proprietary technology that modifies the pharmacokinetic properties of therapeutics. This technology offers several advantages:
- Enhanced Stability: PEGylation helps protect therapeutic molecules from degradation, thereby increasing their stability and shelf life.
- Prolonged Half-Life: Attached polyethylene glycol molecules extend the duration of circulation in the bloodstream, which can enhance the drugs therapeutic effects.
- Reduced Immunogenicity: By changing the surface properties of therapeutic proteins, PEGylation can lower the likelihood of immune reactions against these drugs.
Enzon Pharmaceuticals licenses this innovative platform to other pharmaceutical companies, allowing them to enhance their own drug candidates and improve patient outcomes.
RNA Interference (RNAi) Technology
Enzon Pharmaceuticals is at the forefront of advancing RNA interference (RNAi) technology, a powerful tool for gene silencing. Key features include:
- Targeted Gene Inhibition: RNAi allows for the selective inhibition of disease-causing genes, which can be crucial in the treatment of various conditions including cancer.
- Customization of Therapeutics: Enzon utilizes RNAi to create tailored therapeutic approaches that target specific genetic pathways responsible for diseases.
- Research and Development: Ongoing research into RNAi mechanisms may pave the way for groundbreaking treatments that could revolutionize how certain diseases are managed.
Licensing and Royalties
Enzon Pharmaceuticals engages in strategic licensing agreements to maximize the value of its technologies and drug candidates. This segment includes:
- Technology Licensing: By granting other pharmaceutical firms access to its proprietary technologies, Enzon expands its innovative reach while earning revenue.
- Upfront Payments and Milestone Payments: Enzon generates immediate financial returns through upfront fees and can receive additional payments upon achieving specific development milestones.
- Royalty Income: Long-term revenue is bolstered by royalties derived from the commercial sales of products that utilize Enzon’s technologies, providing a steady income stream.
Conclusion
Enzon Pharmaceuticals Inc. stands as a multifaceted biopharmaceutical company dedicated to the development of high-quality therapeutics through a diverse portfolio of products and services. Their commitment to innovation is reflected in their focus on contract manufacturing, proprietary drug development, the transformative PEGylation platform, RNAi technology, and strategic licensing agreements. By continuously advancing their capabilities, Enzon aims to improve the lives of patients affected by critical health challenges.
1. Contract Manufacturing and Services
Enzon Pharmaceuticals provides robust contract manufacturing and services tailored to the needs of pharmaceutical and biotechnology companies. This segment encompasses a wide array of offerings:
- Process Development: Enzon’s team assists clients in optimizing manufacturing processes for drug candidates, ensuring they are cost-effective and scalable for production.
- Formulation Development: They provide expertise in developing drug formulations that enhance the delivery and effectiveness of active pharmaceutical ingredients (APIs).
- Clinical Manufacturing: The company manages the production scale necessary for clinical trials, adhering to stringent regulatory standards to ensure safety and efficacy in studies.
- Commercial Manufacturing: Enzon’s facilities are equipped to handle large-scale production to meet market demands, ensuring timely delivery of products.
- Analytical Testing: Comprehensive analytical services are offered to confirm the quality, purity, and potency of pharmaceuticals, utilizing advanced testing methodologies to comply with regulatory requirements.
By capitalizing on their state-of-the-art facilities and industry knowledge, Enzon Pharmaceuticals plays a critical role in enabling other companies to successfully bring their therapies to market.
Proprietary Drug Development
Enzon Pharmaceuticals invests significantly in proprietary drug development, focusing on innovative therapeutic candidates that target unmet medical needs. Key aspects include:
- Drug Discovery: Utilizing advanced drug design and screening technologies, Enzon seeks to identify novel compounds that have therapeutic potential.
- Clinical Development: The company manages the progression of drug candidates through various phases of clinical trials, rigorously assessing safety and efficacy for regulatory submissions.
- Therapeutic Areas: Enzons drug development efforts target a variety of diseases, with a primary focus on cancer and autoimmune disorders, striving to improve treatment outcomes for patients.
PEGylation Platform
The PEGylation platform developed by Enzon Pharmaceuticals is a proprietary technology that modifies the pharmacokinetic properties of therapeutics. This technology offers several advantages:
- Enhanced Stability: PEGylation helps protect therapeutic molecules from degradation, thereby increasing their stability and shelf life.
- Prolonged Half-Life: Attached polyethylene glycol molecules extend the duration of circulation in the bloodstream, which can enhance the drugs therapeutic effects.
- Reduced Immunogenicity: By changing the surface properties of therapeutic proteins, PEGylation can lower the likelihood of immune reactions against these drugs.
Enzon Pharmaceuticals licenses this innovative platform to other pharmaceutical companies, allowing them to enhance their own drug candidates and improve patient outcomes.
RNA Interference (RNAi) Technology
Enzon Pharmaceuticals is at the forefront of advancing RNA interference (RNAi) technology, a powerful tool for gene silencing. Key features include:
- Targeted Gene Inhibition: RNAi allows for the selective inhibition of disease-causing genes, which can be crucial in the treatment of various conditions including cancer.
- Customization of Therapeutics: Enzon utilizes RNAi to create tailored therapeutic approaches that target specific genetic pathways responsible for diseases.
- Research and Development: Ongoing research into RNAi mechanisms may pave the way for groundbreaking treatments that could revolutionize how certain diseases are managed.
Licensing and Royalties
Enzon Pharmaceuticals engages in strategic licensing agreements to maximize the value of its technologies and drug candidates. This segment includes:
- Technology Licensing: By granting other pharmaceutical firms access to its proprietary technologies, Enzon expands its innovative reach while earning revenue.
- Upfront Payments and Milestone Payments: Enzon generates immediate financial returns through upfront fees and can receive additional payments upon achieving specific development milestones.
- Royalty Income: Long-term revenue is bolstered by royalties derived from the commercial sales of products that utilize Enzon’s technologies, providing a steady income stream.
Conclusion
Enzon Pharmaceuticals Inc. stands as a multifaceted biopharmaceutical company dedicated to the development of high-quality therapeutics through a diverse portfolio of products and services. Their commitment to innovation is reflected in their focus on contract manufacturing, proprietary drug development, the transformative PEGylation platform, RNAi technology, and strategic licensing agreements. By continuously advancing their capabilities, Enzon aims to improve the lives of patients affected by critical health challenges.